Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.40 |
| ▸ | DRD4 | P21917 | 3/20 | 0.40 |
| ▸ | DRD3 | P35462 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | CBFB | Q13951 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4723337 | 0.88 | MCHR1 (0.41) | ALDH1A1SMN1; SMN2DRD2DRD3 | |
| SCHEMBL4723386 | 0.87 | CYP1A2 (0.44) | HSD17B10DRD2DRD3 | |
| SCHEMBL2091027 | 0.80 | MCHR1 (0.41) | ALDH1A1KDM4E | |
| SCHEMBL9169502 | 0.77 | NOTUM (0.44) | ALDH1A1MAPTHTTHSD17B10SMN1; SMN2 | |
| SCHEMBL2092058 | 0.75 | HCAR1 (0.40) | MAPTKDM4E | |
| SCHEMBL5104125 | 0.74 | ALDH1A1 (0.49) | ALDH1A1CACNA2D1MAPTHTTHSD17B10 | |
| SCHEMBL20897188 | 0.71 | ALDH1A1 (0.49) | ALDH1A1CACNA2D1MAPTHTTHSD17B10 | |
| SCHEMBL1882925 | 0.70 | IDO1 (0.51) | ALDH1A1CACNA2D1MAPTHSD17B10SMN1; SMN2 | |
| SCHEMBL535419 | 0.69 | MGLL (0.37) | ALDH1A1MAPTHTTSMN1; SMN2KDM4E | |
| SCHEMBL4723413 | 0.69 | ALDH1A1 (0.46) | ALDH1A1CACNA2D1MAPTHTTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | PFIZER INC. | 2008-07-24 | — | — | US | disclosed |
| EP-1874780-A1 | 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | Pharmacia & Upjohn Company LLC (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006100591-A1 | 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | TBXA2R, P2RY4, PF4 | ALDH1A1 622/4885CACNA2D1 2309/4885MAPT 4361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.